GlassScriptPhysician profile
James Alden Crouch
NPI 1720303753
$260.39
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $40.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $53.97 | 2019-2020 | |
| Amgen INC. | $53.24 | 2019 | |
| Genentech USA, INC. | $32.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.38 | 2019 | |
| Vifor Pharma, INC. | $20.80 | 2020 | |
| Mylan Specialty L.P. | $19.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.82 | 2019 | |
| Lifescan, INC. | $13.17 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Crouch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.